Intensified Adjuvant Treatment of Prostate Carcinoma: Feasibility Analysis of a Phase I/II Trial

Table 4

(a) Actuarial 5-year late toxicity-free survival (RTOG-EORTC). (b) Impact of treatment parameters on 5-year late toxicity-free survival (RTOG-EORTC); values are in percentages.

(a)  

Toxicity	Grade
	1	2	3	4
Gastrointestinal	85.4%	96.3%	100.0%	100.0%
Genitourinary	76.5%	87.3%	94.2%	100.0%

(b)  

Toxicity	Age (years)			Dose (Gy)			ENI			AHT
	≤65	>65	𝑃 =	64.8	70.2	𝑃 =	No	Yes	𝑃 =	No	BIC	LRA	𝑃 =
GI ≥ 2	95.2	97.9	0.538	100	95.7	0.348	97.7	95.3	0.425	97.1	94.8	97.2	0.849
GU ≥ 2	86.3	89.0	0.584	100	85.2	0.097	85.2	88.4	0.634	87.7	90.6	85.0	0.893
GU ≥ 3	94.0	95.4	0.781	100	93.2	0.356	93.1	95.4	0.243	95.8	97.7	90.3	0.380

BIC: bicalutamide; ENI: elective nodal irradiation; AHT: adjuvant hormonal therapy; LRA: LH-RH agonists; and ys: years.